Quale sarebbe il prezzo per Sorrento Therapeutics, Inc. (0L85)

Il prezzo per Sorrento Therapeutics, Inc. (0L85) è $0.0033

Qual è la capitalizzazione di mercato per Sorrento Therapeutics, Inc. (0L85)

La capitalizzazione di mercato per Sorrento Therapeutics, Inc. (0L85) è $1.79M

Sorrento Therapeutics, Inc. (0L85) Prezzo e Capitalizzazione di Mercato

Sorrento Therapeutics, Inc. is a biopharmaceutical firm, active in both clinical development and commercialization, dedicated to creating treatments across a broad spectrum of illnesses, including cancer, autoimmune conditions, inflammatory disorders, viral infections, and neurodegenerative diseases. The company conducts its operations through two distinct divisions: Sorrento Therapeutics and Scilex. For cancer treatment, Sorrento employs its unique G-MAB antibody library alongside sophisticated targeted delivery methods. These include chimeric and dimeric antigen receptor T-cell (CAR-T) therapies, antibody-drug conjugates, and bispecific antibody strategies. Additionally, its Sofusa drug delivery system enables the direct administration of biologics into the lymphatic system. Sorrento's pipeline features several clinical-stage programs. These encompass an anti-CD38 CAR-T therapy targeting multiple myeloma, amyloidosis, and graft-versus-host disease. The company is also advancing resiniferatoxin, a non-opioid TRPV1 agonist neurotoxin, for managing pain associated with late-stage cancer and osteoarthritis of the knee. Furthermore, ZTlido, a lidocaine delivery system, addresses postherpetic neuralgia. In the realm of pain management, SEMDEXA, an injectable viscous gel, is undergoing Phase III trials for sciatica (a form of lower back pain); SP-103, an experimental non-aqueous lidocaine topical system, is being developed for chronic low back pain; and SP-104 is a novel, low-dose, delayed-release naltrexone hydrochloride formulation for fibromyalgia. The company maintains several strategic collaborations, including a partnership with SmartPharm Therapeutics Inc. for a gene-encoded antibody vaccine against COVID-19, and with Celularity, Inc. for a Phase I/II clinical trial involving up to 94 COVID-19 patients. Additionally, Sorrento works with Mount Sinai Health System on COVI-SHIELD, an antibody treatment for SARS-CoV-2 infection, and with Mayo Clinic on a Phase Ib pilot study utilizing Sofusa technology for Ipilimumab delivery in melanoma patients. Established in 2006, Sorrento Therapeutics operates from its headquarters in San Diego, California.

Il prezzo per 0L85	Attivo B	Capitalizzazione del mercato a B	Risultati
$10,037.36 $1.79M	NVDA	$5.452T	+304,162,384.59%
$8,266.52 $1.79M	AAPL	$4.490T	+250,500,417.86%
$7,663.35 $1.79M	GOOG	$4.162T	+232,222,712.92%
$6,768.47 $1.79M	MSFT	$3.676T	+205,104,921.85%
$5,215.88 $1.79M	AMZN	$2.833T	+158,056,794.65%

Il prezzo per 0L85

Attivo B

Capitalizzazione del mercato a B

Risultati

$10,037.36 $1.79M